American Society for Microbiology defines virus-like particles (VLP’s) as non-infectious multiprotein structure that are engineered to self-assemble from viral structure proteins. VLP technology proves to be a very powerful tool involved in development of vaccines. Several VLP based vaccines exist in the global market involving hepatitis B virus and human papillomavirus.
The virus-like particles (VLP’s) market majorly comprises of top players involving Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India Pvt. Ltd., BHARAT BIOTECH, LG Chem, and VBI Vaccines Inc.
Serum Institute of India Pvt. Ltd. And GlaxoSmithKline plc – Notable Market Players in Virus-like Particles (VLP’s) Market
The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving market position.
Below is the list of the growth strategies done by the players operating in the virus-like Particles (VLP’s) market:
| Year | News |
| December-2021 | Serum Institute of India Pvt. Ltd (SIIPL) announced partnership with Dynavax Technologies Corporation a biopharmaceutical company focused on development and commercializing novel vaccines. The partnership aims that the first participant has been dosed in the Phase-1 part of Phase 1/2 clinical trial pinpointing SIIPL’s vaccine candidate adjuvanted with “CpG 1018” for preventing COVID-19. |
| March-2021 | GlaxoSmithKline (GSK) along with Medicago, a biopharmaceutical company announced starting of Phase 3 clinical testing of Medicago’s plant derived COVID-19 vaccine candidate aiming GSK’s pandemic adjuvant. Medicago’s plant-derived vaccine candidate is effective against COVID-19 comprises of Corona-like-Particle (C0VLP) technology and vaccine composes of recombinant spike glycoprotein expressed as VLP co-administered with GSK’s pandemic adjuvant. |
